葡萄糖-6-磷酸脱氢酶缺乏症溶血风险相关物质的研究进展

doi:10.19803/j.1672-8629.20211165

中国药物警戒 ›› 2023, Vol. 20 ›› Issue (1): 110-116.
DOI: 10.19803/j.1672-8629.20211165

葡萄糖-6-磷酸脱氢酶缺乏症溶血风险相关物质的研究进展

李津婴^1,2, 宋洪杰³, 李津杞^1,2, 顾海慧^1,2, 钱宝华^1,2,*

¹海军军医大学第一附属医院输血科,上海 200433;
²全军儿童溶血性贫血研究创新基地,上海 200433;
³海军军医大学第一附属医院药剂科,上海 200433

收稿日期:2021-01-14 发布日期:2023-01-19
通讯作者: ^*钱宝华,男,教授·博导,主任医师,输血治疗学。E-mail：qianbh1963@163.com
作者简介:李津婴,女,博士,研究员,实验血液学。
基金资助:
国家自然科学基金资助项目（81970165）; 医院“234学科攀峰计划”（2020YXK036）

Research progress in substances related to hemolysis risk in glucose-6-phosphate dehydrogenase deficiency

LI Jinying^1,2, SONG Hongjie³, LI Jinqi^1,2, GU Haihui^1,2, QIAN Baohua^1,2,*

¹Department of Transfusion Medicine, Shanghai 200433, China;
²PLA Research & Innovation Base of Pediatric Hemolytic Anemia, Shanghai 200433, China;
³Department of Pharmacy, the First Affiliated Hospital of Naval Medical University, Shanghai 200433, China

Received:2021-01-14 Published:2023-01-19

摘要/Abstract

摘要： 药物性溶血是葡萄糖-6-磷酸脱氢酶缺乏症（G6PDd）发生急性溶血的常见诱因之一,随着新药研发和面市,涉及G6PDd溶血的药物逐年增加。本文分类介绍对G6PDd有溶血风险的抗生素、抗病毒、抗肿瘤药物,解热镇痛消炎药,代谢类药物,扩血管药物,麻醉剂,解毒剂,其他药物,中草药、植物,外用药、试剂、化学品及食品,为临床医生治疗选择和病患警示预防提供参考。

关键词: 葡萄糖-6-磷酸脱氢酶缺乏症, 溶血风险, 高铁血红蛋白血症, 药物, 化学品, 食物

Abstract: Drug-induced hemolysis is one of the common causes of acute hemolysis in glucose-6-phosphate dehydrogenase deficiency (G6PDd). With the development and marketing of new drugs, cases of drug-induced hemolysis in G6PDd are increasing year by year. This paper lists and updates antibiotics, antivirals, antineoplastics, antipyretics, anti-inflammatory drugs, metabolic drugs, vasodilators, anaesthetics, antidotes, other drugs, herbs, plants, topical drugs, reagents, chemicals and food with hemolysis risk for G6PDd so as to facilitate clinical selection of treatments and warning and prevention of this disease.

Key words: glucose-6-phosphate dehydrogenase deficiency, hemolysis risk, methemoglobinemia, drugs, chemical, food

中图分类号:

R994.11

李津婴, 宋洪杰, 李津杞, 顾海慧, 钱宝华. 葡萄糖-6-磷酸脱氢酶缺乏症溶血风险相关物质的研究进展[J]. 中国药物警戒, 2023, 20(1): 110-116.

LI Jinying, SONG Hongjie, LI Jinqi, GU Haihui, QIAN Baohua. Research progress in substances related to hemolysis risk in glucose-6-phosphate dehydrogenase deficiency[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 110-116.

参考文献

[1] RENARD D, ROSSELET A.Drug-induced hemolytic anemia: Pharmacological aspects[J]. Transfus Clin Biol, 2017, 24(3): 110-114.
[2] LUZZATTO L, ALLY M, NOTARO R.Glucose-6-phosphate dehydrogenase deficiency[J]. Blood, 2020, 136(11): 1225-1240.
[3] LI JY, LI JQ, QIAN BH, et al.Drug-induced hemolysis in glucose-6-phosphate dehydrogenase deficiency: an update[J]. Chinese Journal of Pediatrics(中华儿科杂志), 2021, 59(6): 522-525
[4] BAIRD JK.8-aminoquinoline therapy for latent malaria[J]. Clin Microbiol Rev, 2019, 32(4) : e00011-e00019.
[5] ONORI ME, RICCIARDI TC, URBANI A, et al.Glucose-6-phosphate dehydrogenase deficiency and hydroxychloroquine in the COVID-19 era: a mini review[J]. Mol Biol Rep, 2021, 48(3): 2973-2978.
[6] DAR SA, WAHID M, HAQUE S, et al.Hydroxychloroquine (HCQ) use in G6PD deficient COVID-19 patients and the risk of Acute Hemeolytic Anaemia (AHA)[J]. Eur Rev Med Pharmacol Sci, 2020, 24(15): 7923-7924.
[7] LUZZATTO L, NANNELLI C, NOTARO R.Glucose-6-phosphate dehydrogenase deficiency[J]. Hematol Oncol Clin North Am, 2016, 30(2): 373-393.
[8] DYSOLEY L, KIM S, LOPES S, et al.The tolerability of single low dose primaquine in glucose-6-phosphate deficient and normal falciparum-infected Cambodians[J]. BMC Infect Dis, 2019, 19(1): 250-250.
[9] LACERDA MVG, LLANOS-CUENTAS A, KRUDSOOD S, et al.Single-dose tafenoquine to prevent relapse of plasmodium vivax malaria[J]. N Engl J Med, 2019, 380(3): 215-228.
[10] BELFIELD KD, TICHY EM.Review and drug therapy implications of glucose-6-phosphate dehydrogenase deficiency[J]. Am J Health Syst Pharm, 2018, 75(3): 97-104.
[11] BRANDT O, RIEGER A, GEUSAU A, et al.Peas, beans, and the pythagorean theorem- the relevance of glucose-6-phosphate dehydrogenase deficiency in dermatology[J]. J Dtsch Dermatol Ges, 2008, 6(7): 534-539.
[12] YOUNGSTER I, ARCAVI L, SCHECHMASTER R, et al.Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review[J]. Drug Saf, 2010, 33(9): 713-726.
[13] TANG MX, XIA S.Acute hemolytic anemia induced by tegafur, gimeracil and oteracil potassium capsules[J]. Adverse Drug Reactions Journal(药物不良反应杂志), 2012, 23(4): 240-242
[14] FEGHALY J, AL HOUT AR, MERCIECA BM. Aspirin safety in glucose-6-phosphate dehydrogenase deficiencypatients with acute coronary syndrome undergoing percutaneous coronary intervention[J]. BMJ Case Rep, 2017: bcr-2017-220483.
[15] MINUCCI A, DE LUCA D, TORTI E, et al.Acute haemolytic crisis due to concomitant presence of infection and possible altered acetaminophen catabolism in a Philipino child carrying the G6PD-Vanua Lava mutation[J]. Ann Clin Biochem, 2011, 48(Pt 3): 282-285.
[16] HAGAG AA, BADRAIA IM, ELFARARGY MS, et al.Study of glucose-6-phosphate dehydrogenase deficiency: 5 years retrospective egyptian study[J]. Endocr Metab Immune Disord Drug Targets, 2018, 18(2): 155-162.
[17] ROBINSON KM, YANG W, HAIDAR CE, et al.Concordance between glucose-6-phosphate dehydrogenase (G6PD) genotype and phenotype and rasburicase use in patients with hematologic malignancies[J]. Pharmacogenomics J, 2019, 19(3): 305-314.
[18] MANGANELLI G, FICO A, MARTINI G, et al.Discussion on pharmacogenetic interaction in G6PD deficiency and methods to identify potential hemolytic drugs[J]. Cardiovasc Hematol Disord Drug Targets, 2010, 10(2): 143-150.
[19] KHAN U, HADID T.Rush for G6PD![J]. Blood, 2016 128(23): 2742.
[20] GOI T, SHIONOYA Y, SUNADA K, et al.General anesthesia in a glucose-6-phosphate dehydrogenase deficiency child: a case report[J]. Anesth Prog, 2019, 66(2): 94-96.
[21] DEPTA A, ERD G, WERNER C.Anesthesia in patients with glucose-6-phosphate dehydrogenase deficiency: case report and perioperative anesthesiologic management[J]. Anaesthesist, 2005, 55: 550-554.
[22] REHMAN A, SHEHADEH M, KHIRFAN D, et al. Severe acute haemolytic anaemia associated with severe methaemoglobinaemia in a G6PD-deficient man[J]. BMJ Case Rep, 2018: bcr-2017-223369.
[23] BALWANI MR, BAWANKULE CP, RAMTEKE V, et al.Methylene blue induced methemoglobinemia with acute kidney injury in a glucose-6-phosphateDehydrogenase-deficient patient[J]. Indian J Nephrol, 2017, 27(6): 465-467.
[24] FRANCIS RO, JHANG JS, PHAM HP, et al.Glucose-6-phosphate dehydrogenase deficiency in transfusion medicine: the unknown risks[J]. Vox Sang, 2013, 105(4): 271-282
[25] LEE SW, LAI NM, CHAIYAKUNAPRUK N, et al.Adverse effects of herbal or dietary supplements in G6PD deficiency: a systematic review[J]. Br J Clin Pharmacol, 2017, 83(1): 172-179.
[26] LO YH, MOK KL. High dose vitamin C induced methemoglobinemia and hemolytic anemia in glucose-6-phosphate dehydrogenase deficiency[J]. Am J Emerg Med, 2020, 38(11): 2488.e3-2488.e5
[27] LAI S, HUANG YQ, LIU AQ, et al.Haemolysis during sodium dimercaptosulphonate therapy for Wilson's disease in G6PD-deficient patients: first report of two cases[J]. J Clin Pharm Ther, 2017, 42(6): 783-785.
[28] RAD S, RAMESHRAD M, HOSSEINZADEH H.Toxicology effects of Berberis vulgaris (barberry) and its active constituent, berberine: a review[J]. Iran J Basic Med Sci, 2017, 20(5): 516-529.
[29] ZEKAVAT OR, MAKAREM A, BAHRAMI R, et al.Relationship of glucose-6-phosphate dehydrogenase deficiency and neonatal sepsis: a single-center investigation on the major cause of neonatal morbidity and mortality[J]. Pediatric Health Med Ther, 2019, 10: 33-37.
[30] PERINET I, LIOSON E, TICHADOU L, et al.Hemolytic anemia after voluntary ingestion of henna (Lawsonia inermis) decoction by a young girl with G6PD deficiency[J]. Med Trop (Mars), 2011, 71(3): 292-294.
[31] ZUCCOTTI GV, REDAELLI F, GUALDI V, et al.Hemolytic crisis in a G6PD-deficient infant after ingestion of pumpkin[J]. Ital J Pediatr, 2014, 40: 71.
[32] VIEILLE SL, LEFEBVRE DE, KHALID AF, et al.Dietary restrictions for people with glucose-6-phosphate dehydrogenase deficiency[J]. Nutr Rev, 2019, 77(2): 96-106.
[33] EHELEPOLA N, ABAYAGUNAWARDANA AN, SUDUSINGHE TN.A vegetable-induced hemolytic crisis in a G6PD deficient person: a case report[J]. BMC Res Notes, 2018, 11(1): 179.
[34] BICHALI S, BRAULT D, MASSEROT C, et al.Maternal consumption of quinine-containing sodas may induce G6PD crises in breastfed children[J]. Eur J Pediatr, 2017, 176: 1415-1418.

葡萄糖-6-磷酸脱氢酶缺乏症溶血风险相关物质的研究进展

Research progress in substances related to hemolysis risk in glucose-6-phosphate dehydrogenase deficiency

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	郭宁子, 刘丽, 岳瑞齐, 冯慧庆, 杨化新, 魏宁漪, 陈华. 激光衍射法测定西格列他钠粒径分布[J]. 中国药物警戒, 2024, 21(2): 147-151.
[2]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[3]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[4]	靳生菊, 周苗, 张佳宁, 葛宫慧, 张廷剑, 孟繁浩. 新型黄嘌呤氧化酶抑制剂对痛风治疗的研究进展[J]. 中国药物警戒, 2024, 21(2): 223-228.
[5]	王欣, 史磊磊, 张雨涵, 谢允东, 刘继平. 多药耐药相关蛋白转运体在药物性肝损伤中的作用研究进展[J]. 中国药物警戒, 2024, 21(2): 229-234.
[6]	高源, 石伟, 肖小河, 柏兆方, 王伽伯. 特异质型药物性肝损伤体内评价模型研究进展[J]. 中国药物警戒, 2024, 21(1): 33-39.
[7]	刘敏, 陈艳, 刘文东, 王海学. 药物临床试验期间安全性数据快速报告的更新与思考[J]. 中国药物警戒, 2024, 21(1): 98-101.
[8]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[9]	高旭, 彭金娥, 李兴旺, 张伟. 猴痘抗病毒药物及疫苗研究现状[J]. 中国药物警戒, 2024, 21(1): 111-116.
[10]	詹姆斯·布坎南. 用 nR 改良海氏法则及 P_ALT 评估药物性肝损伤研究进展[J]. 中国药物警戒, 2024, 21(1): 117-120.
[11]	马瑞泽, 陈志海. 抗新型冠状病毒的小分子药物最新研究进展[J]. 中国药物警戒, 2023, 20(9): 961-966.
[12]	夏旭东, 黎美霞, 孙阳, 杨胜亚. 药品上市许可持有人药物警戒远程检查流程探讨[J]. 中国药物警戒, 2023, 20(9): 967-970.
[13]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[14]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[15]	沈艳杰, 吴奕卿. 临床试验期间不良事件管理的实践与思考[J]. 中国药物警戒, 2023, 20(9): 982-986.